Document Detail

Erythropoietin-induced erythroid precursor pool depletion causes erythropoietin hyporesponsiveness.
MedLine Citation:
PMID:  23187865     Owner:  NLM     Status:  MEDLINE    
PURPOSE: The purpose of this study is to demonstrate that the erythroid precursor depletion in bone marrow induced by recombinant human erythropoietin (rHuEPO) treatment may be another contributing factor to erythropoietin hyporesponsiveness.
METHODS: Healthy Wistar rats were given single dose (SD) or multiple doses (MD) of rHuEPO (100 IU/kg). In MD study, animals were challenged with thrice-weekly over two weeks. Blood, bone marrow and spleen (for SD only) were collected. The erythropoietic responses in bone marrow and spleen were quantified using a flow cytometric immunophenotyping technique. A mathematical approach involving measuring reticulocyte age distribution was developed to evaluate the reticulocyte loss due to neocytolysis.
RESULTS: A reduced level of erythropoietic responses below the baseline was observed for both MD and SD studies. In SD study, the reticulocyte decreased below the baseline after day 6. A depletion of the bone marrow erythroid precursor cells was observed. However, neocytolysis of reticulocyte only occurs from day 3-5 after rHuEPO injection.
CONCLUSIONS: The findings demonstrate that EPO-induced erythroid precursor depletion in bone marrow is responsible for reduced reticulocyte response and may contribute to erythropoietin hyporesponsiveness. Therefore, this study provides further justification for reducing the doses of erythropoietin-stimulating agents in anemic patients demonstrating hyporesponsiveness.
Xiaoyu Yan; Sihem Ait-Oudhia; Wojciech Krzyzanski
Related Documents :
1483485 - Objective evidence for tolerance, against a background of improvement, during maintenan...
7517825 - Acute effects of tramadol in methadone-maintained volunteers.
2746265 - The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in parkinson'...
23534465 - Prevention of osteopenia and dyslipidemia in rats after ovariectomy with combined aspir...
510385 - In vivo evidence of partial agonist activity exerted by purported 5-hydroxytryptamine a...
23932835 - Praseodymium-142 microspheres for brachytherapy of nonresectable hepatic tumors.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-11-28
Journal Detail:
Title:  Pharmaceutical research     Volume:  30     ISSN:  1573-904X     ISO Abbreviation:  Pharm. Res.     Publication Date:  2013 Apr 
Date Detail:
Created Date:  2013-03-12     Completed Date:  2013-08-27     Revised Date:  2014-05-27    
Medline Journal Info:
Nlm Unique ID:  8406521     Medline TA:  Pharm Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1026-36     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Intravenous
Bone Marrow / drug effects
Erythroid Precursor Cells / drug effects*
Erythropoiesis / drug effects
Erythropoietin / administration & dosage,  adverse effects,  blood,  pharmacology*
Rats, Wistar
Recombinant Proteins / administration & dosage,  adverse effects,  blood,  pharmacology*
Reticulocytes / drug effects
Spleen / drug effects
Grant Support
Reg. No./Substance:
0/Recombinant Proteins; 11096-26-7/Erythropoietin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Microporation and 'iron'tophoresis for treating iron deficiency anemia.
Next Document:  Investigation of follicular and non-follicular pathways for polyarginine and oleic acid-modified nan...